UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, E9
Other Events
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
Corporate Presentation January 2026
Ampreloxetine KOL Event December 8, 2025
Third Quarter 2025 Financial Results and Business Update
Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
FY 2025
Q3
Q2
Q1
FY 2024
SC TO-I
Tender Offer Statement by Issuer
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Notice of Proposed Sale of Securities
Amended Tender Offer Statement by Issuer
Correspondence